Advanced Accelerator Applications clinical trials
Acquired by Novartis, Jan 22, 2018 · source ↗
The registry lists 17 studies whose lead sponsor is Advanced Accelerator Applications. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 28, 2026.
- 17studies on the registry
- 0open to participants now
- 1phase 3 study under way
- 1reach primary completion within a year
Before and after it joined Novartis
- First submitted before Advanced Accelerator Applications became part of Novartis
- 8
- First submitted after Advanced Accelerator Applications became part of Novartis
- 9
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Advanced Accelerator Applications’s studies test, most studies first; none is open now — 6 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- lutetium Lu 177 dotatate2 in phase 30 open · 2
- 0 open · 1
- 0 open · 1
- 0 open · 1
- 0 open · 1
- Rubidium-821 in phase 30 open · 1
Coming up
1 of Advanced Accelerator Applications’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- 1SSep
- OOct
- NNov
The study
- Sep 2027Post-Authorization Long-Term Safety Study of LUTATHERANCT03691064
Add it to your calendar (.ics) → With an account.
All 17 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 418
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Advanced Accelerator Applications17 studies
Something wrong with this grouping? Tell us on the Novartis page.
Studies
Recruiting first, then most recently updated. Showing 17 of 17. All Novartis studies →
- [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion UptakeCompletedNCT03872778Phase 1/2
Sponsor listed in the registry: Advanced Accelerator Applications · First submitted after Advanced Accelerator Applications became part of Novartis
- Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLsActive, not recruitingNCT04711135Phase 2
Sponsor listed in the registry: Advanced Accelerator Applications · First submitted after Advanced Accelerator Applications became part of Novartis
- Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NETActive, not recruitingNCT03972488Phase 3
Sponsor listed in the registry: Advanced Accelerator Applications · First submitted after Advanced Accelerator Applications became part of Novartis
- Post-Authorization Long-Term Safety Study of LUTATHERAActive, not recruitingNCT03691064
Sponsor listed in the registry: Advanced Accelerator Applications · First submitted after Advanced Accelerator Applications became part of Novartis
- 177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate CancerTerminatedNCT03490838Phase 1
Sponsor listed in the registry: Advanced Accelerator Applications · First submitted after Advanced Accelerator Applications became part of Novartis
- Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) PatientsCompletedNCT04524442Phase 4
Sponsor listed in the registry: Advanced Accelerator Applications · First submitted after Advanced Accelerator Applications became part of Novartis
- 177Lu-PSMA-617 Managed Access Program for mCRPC PatientsNo longer availableNCT04825652
Sponsor listed in the registry: Advanced Accelerator Applications · First submitted after Advanced Accelerator Applications became part of Novartis
- A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid TumoursCompletedNCT01578239Phase 3
Sponsor listed in the registry: Advanced Accelerator Applications · First submitted before Advanced Accelerator Applications became part of Novartis
- 99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast CancerTerminatedNCT02677714Phase 2
Sponsor listed in the registry: Advanced Accelerator Applications · First submitted before Advanced Accelerator Applications became part of Novartis
- 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)CompletedNCT03490032Phase 1/2
Sponsor listed in the registry: Advanced Accelerator Applications · First submitted after Advanced Accelerator Applications became part of Novartis
- [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)TerminatedNCT03724253Phase 2
Sponsor listed in the registry: Advanced Accelerator Applications · First submitted after Advanced Accelerator Applications became part of Novartis
- 99mTc-rhAnnexin V-128 Imaging for Carotid AtherosclerosisTerminatedNCT02667457Phase 2
Sponsor listed in the registry: Advanced Accelerator Applications · First submitted before Advanced Accelerator Applications became part of Novartis
- 99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)TerminatedNCT02328027Phase 1/2
Sponsor listed in the registry: Advanced Accelerator Applications · First submitted before Advanced Accelerator Applications became part of Novartis
- 99mTc-rhAnnexin V-128 in Diagnosis of SpondyloarthritisTerminatedNCT03232580Phase 2
Sponsor listed in the registry: Advanced Accelerator Applications · First submitted before Advanced Accelerator Applications became part of Novartis
- 99mTc-rhAnnexin V-128: a First In Man Study in Healthy VolunteersCompletedNCT02182609Phase 1
Sponsor listed in the registry: Advanced Accelerator Applications · First submitted before Advanced Accelerator Applications became part of Novartis
- EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA TxApproved for marketingNCT02705313
Sponsor listed in the registry: Advanced Accelerator Applications · First submitted before Advanced Accelerator Applications became part of Novartis
- Rubidium-82 PET and Tc-99m-MIBI SPET: A Head to Head ComparisonCompletedNCT01379677Phase 3
Sponsor listed in the registry: Advanced Accelerator Applications · First submitted before Advanced Accelerator Applications became part of Novartis